Although PD-1/PD-L1 blockade has been used for CTCL and the anti–PD-L1 inhibitor durvalumab is currently evaluated in a phase I/II clinical trial in combination with lenalidomide in patients with refractory/relapsed CTCL (27) (ClinicalTrials.gov NCT03011814), little is known about their biological effects on TAMs in the CTCL TME (28). This evidence concerns the gene PDCD1 and primary cutaneous T-cell non-Hodgkin lymphoma.